- Gene therapies, involving the introduction, removal, or alteration of an individual's genetic material to treat or cure diseases, are increasingly vital components of modern medicine, offering potential cures for previously untreatable genetic disorders, cancers, and infectious diseases in both inherited and acquired conditions due to their targeted approach and disease-modifying potential
- The escalating demand for gene therapies is primarily fueled by the growing understanding of the genetic basis of diseases, significant advancements in gene editing technologies, and a rising need for effective treatments for rare and chronic conditions where conventional therapies offer limited success
- North America dominates the gene therapy market with the largest revenue share of 40.5% in 2025, characterized by strong research infrastructure, high healthcare expenditure, and the presence of leading biotechnology and pharmaceutical companies
- Asia-Pacific is expected to be the fastest growing region in the gene therapy market with a CAGR of 27.2%, during the forecast period due to increasing investments in healthcare infrastructure, a growing patient population with genetic disorders, and rising disposable incomes supporting access to advanced medical treatments
- Viral Vector segment is expected to dominate the gene therapy market with a market share of 85.5% in 2025, driven by the well-established efficacy and versatility of viral vectors such as adeno-associated viruses (AAVs) and lentiviruses in delivering therapeutic genes. These vectors have been extensively studied and successfully used in several approved gene therapies
